Amgen unveils five-year survival data for Blincyto
Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note
Read More
Tag: BiTE
EU expands use of Amgen’s Blincyto
European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.
Read More
Amgen’s Blincyto wins full US approval
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
